Mink Brook Asset Management LLC Acquires Shares of 159,734 MDxHealth SA $MDXH

Mink Brook Asset Management LLC bought a new position in shares of MDxHealth SA (NASDAQ:MDXH) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 159,734 shares of the company’s stock, valued at approximately $743,000. MDxHealth accounts for approximately 0.5% of Mink Brook Asset Management LLC’s holdings, making the stock its 26th biggest position.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Lido Advisors LLC purchased a new stake in MDxHealth in the 3rd quarter worth $48,000. GSA Capital Partners LLP acquired a new stake in shares of MDxHealth in the third quarter valued at about $48,000. Jefferies Financial Group Inc. acquired a new stake in shares of MDxHealth in the third quarter valued at about $53,000. Bank of America Corp DE increased its stake in shares of MDxHealth by 5,164.0% during the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock worth $70,000 after purchasing an additional 14,769 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of MDxHealth during the 3rd quarter worth about $127,000.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on MDXH shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a report on Monday, December 29th. BTIG Research restated a “buy” rating and issued a $7.00 target price on shares of MDxHealth in a research report on Tuesday, December 23rd. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.75.

MDxHealth Stock Up 5.3%

Shares of NASDAQ MDXH opened at $3.37 on Tuesday. The firm has a 50-day simple moving average of $3.52 and a 200-day simple moving average of $3.78. The stock has a market capitalization of $166.82 million, a price-to-earnings ratio of -5.03 and a beta of 1.61. MDxHealth SA has a 52 week low of $1.36 and a 52 week high of $5.33.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings data on Thursday, February 26th. The company reported $999.00 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $999.13. The company had revenue of $29.55 million during the quarter, compared to analysts’ expectations of $26.05 million. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. As a group, equities research analysts expect that MDxHealth SA will post -1.15 EPS for the current year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.